NCT03561285

Antiphospholipid Antibodies & Osteopontin as Risk Factors for Cerebrovascular Stroke in Young Adults

Status unknown Last updated 8 July 2020

What this trial tests

trial testing antiphospholipid Abs in Stroke in Young Adults in 500 participants. Status unknown.

Timeline

1 September 2020

Primary endpoint
1 December 2020

1 December 2020

Quick facts

Lead sponsor	Assiut University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	500
Start date	1 September 2020
Primary completion	1 December 2020
Estimated completion	1 December 2020
Sites	1 location across Egypt

Drugs / interventions tested

• antiphospholipid Abs

Conditions studied

• Stroke in Young Adults — all drugs for Stroke in Young Adults →

Sponsor

Assiut University

Who can join

Adults 18 to 49, any sex, with Stroke in Young Adults. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The burden of stroke is increasing in many low- and middle income countries.(1) Around 10% of all thrombotic cerebrovascular events (CVE) occur in young population defined as younger than 50 years old (2)

In the majority of these patients, the cause of the ischaemic stroke remains undetermined.(3) Arterial thrombosis is a major clinical manifestation of the antiphospholipid syndrome (APS), an autoimmune condition characterised by thrombotic events and/or pregnancy morbidity with persistently positive antiphospholipid antibodies (aPL) (4).

Considering all patients with cerebral ischaemia, the prevalence of aPL seems rather high in young adults, who might constitute a subgroup at high risk for recurrence.(5)

Through the support of the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION), a systematic review aiming to estimate the frequency of clinically significant aPL profiles in the general population (no age limit) was completed. (6)

The pathogenesis of ischemic stroke is complex, and several studies documented hypercoagulable states as a significant mechanism underlying stroke. (8).

The latter include protein C, protein S, or antithrombin III deficiencies, activated protein C resistance and anti-phospholipid antibodies (aPLA), including anticardiolipin (aCL) antibodies or lupus anticoagulant (LAC), which influence stroke susceptibility owing to their capacity to disturb normal hemostatic mechanisms (9).

While aPLA are clinically associated with a state of hypercoagulation and prothrombotic disorders, the exact mechanism underlying their prothrombotic effects remains unknown (10).

aPLA are detected either functionally, owing to their ability to prolong coagulation time in a phospholipid-dependent coagulation test (LAC), or by measuring specific \[anticardiolipin (aCL) and antiphosphatidylserine (aPS)\] antibodies by specific immunoassays, using anionic phospholipids as antigens (11).

The contribution of LAC to the overall risk of both venous and arterial thrombosis, including ischemic stroke, is now well recognized (12).

While the contribution of aPLA (including LAC and aCL antibodies) to thrombosis is well established, their role as independent risk factors in the pathogenesis of ischemic stroke yielded apparently conflicting results. (13).

These conflicting results could be explained by differences in ethnic origin , inherent variation in aPLA levels and in the failure in some studies to account for the contribution of covariates (14).

Osteopontin (OPN) was first identified as a protein involved in bone remodelling, but later also shown to have important immunological roles. (15).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Osteopontin as a Link between Inflammation and Cancer: The Thorax in the Spotlight.
   Lamort AS, Lamort AS, Giopanou I, Psallidas I, et al · · 2019 · cited 130× · PMID 31382483 · DOI 10.3390/cells8080815